comparemela.com

Latest Breaking News On - Professor gianneschi - Page 1 : comparemela.com

How Tiny Polymers Are Outsmarting Neurodegenerative Diseases

A groundbreaking study introduces a new method of targeting 'undruggable' proteins to fight neurodegenerative diseases by enhancing cellular antioxidant defenses, offering new hope for treatment advancements. Researchers led by Northwestern University and the University of Wisconsin-Madison have

Researchers introduce a pioneering approach to combat neurodegenerative diseases

Researchers led by Northwestern University and the University of Wisconsin-Madison have introduced a pioneering approach aimed at combating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis (ALS).

Targeting undruggable proteins promises new

<p>In a new study, researchers discovered a new way to enhance the body&rsquo;s antioxidant response, which is crucial for cellular protection against the oxidative stress implicated in many neurodegenerative diseases. The&nbsp;pioneering approach might inform treatments for neurodegenerative diseases such as Alzheimer&#39;s disease, Parkinson&#39;s disease and Amyotrophic lateral sclerosis (ALS).</p>

Grove Biopharma Launches with a Novel Biotherapeutic Modality Platform; Portal Innovations Leads Oversubscribed Seed-Stage Investment

Grove Biopharma Launches with a Novel Biotherapeutic Modality Platform; Portal Innovations Leads Oversubscribed Seed-Stage Investment Share Article Leverages Biomaterial Discoveries and Insights from Award Winning Scientist Nathan Gianneschi, Ph.D. With an Initial Focus on Neurodegenerative Diseases Professor Gianneschi’s protein-like polymer (PLP) platform is a revolutionary innovation at the interface between materials engineering, biology, chemistry, and data science with the potential to address important biological disease targets including those classically considered to be undruggable. CHICAGO (PRWEB) May 10, 2021 Portal Innovations, a premier life sciences venture development engine, today announced that Grove Biopharma has successfully closed an oversubscribed $4 million seed round and will become a portfolio member at its Fulton Labs location. Other noteworthy participants in the financing include Jo

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.